A venture firm was founded in 2015 with offices in California and Israel. The firm invests in multiple sectors, including the life sciences, and is currently investing out of their third fund, a $450M fund. The firm invests in pre-seed and seed-stage companies; within healthcare, therapeutics, diagnostics and R&D tools companies developing platform technologies. The firm invests early, often acting as the first institutional capital, investing just after the initial stages of product development. The firm generally leads rounds, investing between $.5-5M in rounds no larger than ~$7M. While the firm has to this point invested in US and Israeli companies, it will also consider European and Canadian companies as well.
Within healthcare, the firm is interested in platform technologies in therapeutics and diagnostics/R&D tools. The firm is agnostic to indication and modality, and is looking for companies that have multiple avenues of development to reach the market. Previous investments include companies building CRISPR technologies, post-treatment monitoring, -omics-based drug development, CAR-T and high-throughput screening. The firm does not invest in digital health or medical devices.
The firm acts as a lead investor. Even though they invest early, the firm prefers that the company have at least two full time co-founders before investing. The firm does take a board seat after investing, and is an active investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply